NL-OMON47147已完成不适用
Interventional, randomised, open label, multi-centre, parallel-group, controlled study investigating the effects of using the PReDicT test to guide the antidepressant treatment of depressed patients - PReDicT: Predicting Response to Depression Treatment
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Male or female and aged between 18 and 65 inclusive.
- •- Diagnosed with a depressive episode by a physician (either first episode or
- •recurrent) and requiring treatment with a selective serotonin reuptake
- •inhibitor (SSRI) medication (excluding fluoxetine).
- •- Prescribed an SSRI by a physician for the treatment of depression within
- •the 7 days prior to Visit 1, but has not yet started taking the medication.
- •- Is intending to start SSRI treatment within 7 days of Visit 1.
排除标准
- •- Previous history of mania.
- •- Is currently taking an antidepressant medication or has stopped
- •antidepressant treatment within 2 weeks prior to Visit 1. Participants who are taking or have taken antidepressant medication for treatment of a different condition at a dose which does not have an antidepressant effect are eligible for inclusion.
- •- Requires immediate referral to alternative mental health services (e.g.
- •where patient seen in primary care is referred to secondary care services).
- •- Presents to a physician with significant current suicidal intent requiring
- •enhanced care.
研究者
相似试验
尚未招募
3 期
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentCTRI/2024/07/069956Pfizer Inc.
进行中（未招募）
1 期
Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 antiviral treatment relief strategies, in patients co-infected with the HIV-1 and HBV virusesco-infected with the HIV-1 and HBV virusesCTIS2023-508634-34-00Inserm140
进行中（未招募）
不适用
EMD 525797 in combination with Cetuximab and Irinotecan in k-ras Wildtype Metastatic Colorectal CancerSubjects with k-ras WT, metastatic colorectal cancer who have failed a fist line chemotherapy with an oxaliplatin-containing regimen will be eligible for this trial.MedDRA version: 17.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2009-012040-16-BGMerck KGaA237
进行中（未招募）
不适用
EMD 525797 in combination with Cetuximab and Irinotecan in k-ras Wildtype Metastatic Colorectal CancerEUCTR2009-012040-16-CZMerck KGaA237
进行中（未招募）
不适用
EMD 525797 in combination with Cetuximab and Irinotecan in k-ras Wildtype Metastatic Colorectal CancerSubjects with k-ras WT, metastatic colorectal cancer who have failed a fist line chemotherapy with an oxaliplatin-containing regimen will be eligible for this trial.MedDRA version: 15.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012040-16-DEMerck KGaA237